返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® OrthoRecon Hosts SuperPath™ Training Course

[2017-06-19] 

Shanghai, China – On June 4, Suzhou MicroPort OrthoRecon Co., Ltd. ("MicroPort® OrthoRecon") hosted a training course "Fast to Full Function: SuperPath™ Train the Trainer Course" in Shanghai. Over 30 domestic experts of the orthopedic industry were invited to discuss the surgical experience and development trend of SuperPath™ Micro-posterior Total Hip Arthroplasty ("SuperPath™") with the creator of SuperPath™ Professor Jimmy Chow and his father Professor James Chow, former President of Arthroscopy Association of North America.
 
In the beginning of the course, Professor Jimmy Chow lectured on "the latest development of SuperPath™ technique" and "nine years' experience in using SuperPath™" based on the surgical video of SuperPath™. When introducing his follow-up study, he said: "All of the post-operational dislocation rate, deep vein thrombus ('DVT') rate and deep infection rate of patients undergoing SuperPath™ technique are less than 1%. SuperPath™ can be used not only in primary hip arthroplasty but also in the revision operations. All of my revision cases are started with SuperPath™, and less than 20% need transferring to traditional approach."
 
Afterwards, 10 Chinese orthopedic experts respectively shared their clinical experience in using SuperPath™ which stimulated hot discussions. Professor Jimmy Chow reviewed each case and said: "I surprisingly find that the understanding of Chinese surgeons in SuperPath™ technique has largely improved compared to three or four years ago, even better than some of their US peers, and the number of SuperPath™ cases in China also quickly increased." In addition, Professor Jimmy Chow pointed out, currently MicroPort® OrthoRecon offers two versions of femoral prosthesis - monoblock and modular stem - with the same design rationale, profile and instrument, which makes them the best prosthesis to work with SuperPath™ technique.
 
As the world's first total hip arthroplasty minimally invasive technique that facilitates a faster return to function for patients, SuperPath™ technique not only offers patients with small incision, but also provides added advantages like preservation of the external rotators, decreased operative time, decreased intra-operative blood loss, increased post-operative stability, as well as decreased post-operative recovery time and pain. After being introduced to China in 2014, SuperPath™ technique has been used in 25 provinces and cities of China with the constant efforts of MicroPort® OrthoRecon to help an increasingly more surgeons master the technique, allowing more patients to get a faster return to function and reduced complications. MicroPort® OrthoRecon will continue to promote such innovative technique through similar academic activities as this SuperPath™ training courses and other kinds of academic platforms for SuperPath™ learners and experts, and thereby to promote the development of domestic and international orthopedic business and improve the life quality of worldwide patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 


[Next]:MicroPort® OrthoRecon Project Listed in National Key R&D Plan